Execution OS for personalized gene-medicine programs to release patient-specific lots and coordinate bedside dosing.
ARPA-H rare-disease gene-editing platforms
3.3
Section
Sectors
Rollout OS for diagnostic chains launching Alzheimer's blood tests, with site QC, reference checks, and neurologist routing.
Alzheimer’s blood-test diagnostics
2.9
Resistance benchmark foundry for ADC biotechs to prove next-gen payloads beat TOPO-1 and microtubule ceilings.
ADC payload resistance platform
3.7
Vendor-neutral compiler for automated biology labs that turns SOPs into device-ready runs and recovers failed assays automatically.
Protocol-to-device execution for biology labs
3.6
Partner-readiness OS for Taiwanese biotechs entering Boston, converting delegation meetings into signed licensing and clinical follow-up.
Biotech market-entry rails from Taiwan to Boston
2.7
Radioligand developability OS for radiopharma teams to rank binders, choose isotope pairs, and reach GMP-ready first-in-human studies.
Radiopharma AI-to-clinic partnership
3.3
Contract organ-on-chip data foundry that sells biopharma target-validation teams standardized, model-ready human tissue datasets, not another AI model.
3D bio intelligence data infrastructure
3.6
AR-resistance evidence network that finds prostate-cancer patients and proves target engagement for AR-pathway degrader trials.
Prostate cancer ARON degrader financing
3.6
Genotype-to-referral OS for AATD gene-editing trials that finds untreated PiZZ patients and qualifies centers before launch.
In vivo base editing therapy for rare genetic lung-liver disease
3.2
GMP recipe foundry for beta-cell therapy startups to turn fragile lab differentiation protocols into reproducible functional cell lots.
Cellgorithm cell therapy platform funding
3.7
Multiomic review OS for cancer diagnostics labs to sign off hard noncoding variants and ship defensible reports.
Biological AI with built-in biodefense
3.7
Cross-specialty trial OS for Graves and thyroid eye disease programs to find patients faster and capture dual-disease evidence.
Root-cause thyroid autoimmunity therapies
3.3
Cross-modal biology OS that helps oncology biotechs rank and validate asset combinations before expensive expansion trials.
Biology reasoning layer for drug R&D
4.2
Blood-based immune baseline OS for transplant centers that need earlier, defensible intervention signals before rejection or over-immunosuppression becomes visible.
IMU immune profiling scale-up
3.7
Audit-ready copilot that turns Claude model sessions into reproducible experiment packets for pharma discovery teams.
SandboxAQ puts quantitative models into Claude
3.7
Expression-tuning foundry for mRNA biotechs building chronic-disease therapies that need durable, IND-ready construct data.
ParcelBio mRNA launch
3.7
Enrollment and endpoint platform for retinal gene-therapy trials that finds eligible patients faster and proves functional vision change.
vision-restoration biotech
3.1
Objective endpoint and recruitment layer for CNS biotechs licensing clinical assets and racing to prove signal in noisy trials.
CNS drug pipeline launch
3.4